Dr Thiagarajah Sasikaran (Sasi) works as the Deputy Operations Manager in the division of Surgery within the UKCRC registered Imperial Clinical Trials Unit (ICTU). He joined Imperial College in 2002 and has extensive experience in the delivery of large scale, multi-centre, international clinical trials. His main interest remains focused on innovative trial design and delivery, to enable key questions to be answered quickly and robustly. Adaptive trial designs include multi-arm, multi-stage RCTs (MAMS) and Trials WithIn Cohorts (TWICS).
Sasi currently oversees the full trial management process for the Imperial Prostate (IP) portfolio of studies including CHRONOS (Comparative Health Research Outcomes of Novel Surgery in prostate cancer), ATLANTA (Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms), PROSPECT (PROState Pathway Embedded Comparative Trial) and CHAIROS (Cancer Histology Artificial Intelligence Reliability Study) from applying for funding through to reporting of results.
He has previously managed and delivered numerous multi-centre randomised clinical trials listed below: AVATAR- AF trial (Ablation Versus Anti-arrhythmic Therapy for reducing All hospital episodes from Recurrent Atrial Fibrillation), SERCA-LVAD trial (Investigation of the safety and feasibility of SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device), AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of Ace-inhibition on RisK), FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 inhibition in subjects with Elevated Risks), CVLPRI-t trial (Complete Versus Lesion-only PRimary PCI Pilot) and PILL Pilot (A randomised placebo-controlled trial of fixed-dose combination medication in people at raised risk of cardiovascular disease).
et al., 2021, PROState pathway embedded comparative trial: The IP3-PROSPECT study, Contemporary Clinical Trials, ISSN:1551-7144
et al., 2020, Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL, Gene Therapy, Vol:27, ISSN:0969-7128, Pages:579-590
et al., 2019, Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation (AVATAR-AF): design and rationale, American Heart Journal, Vol:214, ISSN:0002-8703, Pages:36-45
Sasikaran T, Johnson N, Daycase Cryo-balloon Ablation Without Pulmonary Vein Mapping Versus A Conventional Cryo-balloon Approach: Quality Of Life Results From The Prospective, Randomised, Multi-Center AVATAR-AF Trial, 2020 Heart Rhythm Society Scientific Session
Johnson NA, Sasikaran T, 2019, AVATAR-AF: Getting to the heart of data management for analysis (5 simple rules to follow to ensure data integrity), 5th International Clinical Trials Methodology Conference, BMC